Loading...
XNAS
HSDT
Market cap580kUSD
Jun 06, Last price  
1.10USD
1D
-3.51%
1Q
144.44%
Jan 2017
-99.95%
IPO
-99.97%
Name

Helius Medical Technologies Inc

Chart & Performance

D1W1MN
P/E
P/S
1.12
EPS
Div Yield, %
Shrs. gr., 5y
347.75%
Rev. gr., 5y
-19.05%
Revenues
520k
-19.25%
00000478,0001,496,000661,000522,000787,000644,000520,000
Net income
-12m
L+32.68%
0-1,067,284-8,894,555-12,040,000-28,024,000-28,623,0004,339,000-13,937,000-18,122,000-12,558,000-8,850,000-11,742,000
CFO
-11m
L+6.00%
-12,014-348,698-6,321,285-7,885,000-19,325,000-19,621,000-20,999,000-11,738,000-13,388,000-14,310,000-10,416,000-11,041,000
Earnings
Aug 11, 2025

Profile

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
IPO date
Jun 27, 2014
Employees
19
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
520
-19.25%
644
-18.17%
787
50.77%
Cost of revenue
4,241
3,525
4,725
Unusual Expense (Income)
NOPBT
(3,721)
(2,881)
(3,938)
NOPBT Margin
Operating Taxes
(1,514)
Tax Rate
NOPAT
(3,721)
(2,881)
(2,424)
Net income
(11,742)
32.68%
(8,850)
-29.53%
(12,558)
-30.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,961
500
18,644
BB yield
Debt
Debt current
12
90
54
Long-term debt
12
69
166
Deferred revenue
128
175
Other long-term liabilities
320
3,323
6,917
Net debt
(1,064)
(5,023)
(14,329)
Cash flow
Cash from operating activities
(11,041)
(10,416)
(14,310)
CAPEX
(5)
(29)
(17)
Cash from investing activities
(5)
(29)
(11)
Cash from financing activities
6,954
1,077
17,869
FCF
(3,299)
(2,942)
(2,676)
Balance
Cash
1,088
5,182
14,549
Long term investments
Excess cash
1,062
5,150
14,510
Stockholders' equity
(171,362)
(160,629)
(151,467)
Invested Capital
172,753
166,532
166,820
ROIC
ROCE
EV
Common stock shares outstanding
27,098
608
270
Price
Market cap
EV
EBITDA
(3,685)
(2,719)
(3,683)
EV/EBITDA
Interest
834
Interest/NOPBT